Access & Legality
    Retatrutide

    Retatrutide Telehealth Prescriptions

    Telehealth has revolutionized access to weight loss medications, eliminating geographic barriers and reducing costs. Here is how telehealth prescribing works and how it positions you for retatrutide access.

    Published: April 3, 2026•12 min read

    The telehealth revolution has made weight loss medications accessible to millions who could not previously obtain them -- patients in rural areas without obesity medicine specialists, patients who cannot take time off work for monthly clinic visits, and patients priced out of brand-name medications. As retatrutide moves toward availability (Jastreboff et al., NEJM 2023), telehealth providers will be at the forefront of patient access, just as they have been for semaglutide and tirzepatide.

    Current Availability

    Retatrutide is not yet FDA-approved. Telehealth access to retatrutide specifically is limited. Currently available through telehealth: compounded semaglutide and tirzepatide with full medical oversight.

    How Telehealth Weight Loss Treatment Works

    The process is straightforward and typically takes less than a week from initial consultation to receiving medication at your door. You complete an online medical questionnaire covering your health history, current medications, weight loss goals, and any contraindications. A licensed provider reviews your information and conducts a consultation (video or asynchronous depending on the platform). If appropriate, the provider prescribes medication and sends it to a partnered compounding pharmacy. The pharmacy compounds and ships the medication directly to your home with injection supplies and instructions.

    What Makes a Good Telehealth Provider

    • Licensed providers: Board-certified physicians, NPs, or PAs with weight management experience
    • Ongoing monitoring: Regular check-ins, dose titration guidance, and lab monitoring
    • Transparent pricing: No hidden fees, membership charges, or surprise costs
    • Vetted pharmacy partners: Licensed compounding pharmacies with quality standards
    • Responsive support: Access to medical team for questions and side effect management
    • Evidence-based protocols: Treatment based on clinical guidelines, not marketing

    Available Now Through Telehealth

    While retatrutide access expands, highly effective weight loss medications are available through telehealth today. TRIMI offers compounded semaglutide from $99/mo and compounded tirzepatide from $125/mo. These medications produce significant weight loss (15-22%) with the convenience and affordability of telehealth-based care. Establishing a telehealth relationship now means seamless access to new medications like retatrutide as they become available.

    Visit our treatments page to explore your options.

    Medical Disclaimer

    This article is for educational purposes only. Retatrutide is not FDA-approved. Telehealth prescribing regulations vary by state. Consult with a licensed healthcare provider for treatment decisions.

    Start Treatment From Home

    Telehealth weight loss treatment. Semaglutide from $99/mo, tirzepatide from $125/mo.

    Get Started Today

    More on Retatrutide

    How to Get Retatrutide in 2026

    All access pathways

    Retatrutide Waitlist: How to Be First

    Positioning for early access

    Compounded Retatrutide Safety

    Safety of compounded forms

    Retatrutide Insurance Coverage

    Coverage and cost outlook

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 19, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    — Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    — Lynn SchweitzerFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Provider & Access

    Online Semaglutide Weight Loss Programs

    Clinician-reviewed Trimi guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares to brand alternatives.

    8 minRead More
    Provider & Access

    Semaglutide Weight Loss Online Guide

    Clinician-reviewed Trimi guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares to brand alternatives.

    8 minRead More
    Provider & Access

    GLP-1 Online Prescription How to Get

    Clinician-reviewed Trimi guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares to brand alternatives.

    8 minRead More
    Provider & Access

    How Online GLP-1 Prescriptions

    Clinician-reviewed Trimi guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares to brand alternatives.

    8 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started